Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertram Pitt

Showing results (551-560 of 688) with videos related to

Pageof 69
Sort By:
European Journal of Heart Failure|March 2, 2026
Efficacy of finerenone in patients with heart failure and mildly reduced or preserved ejection fraction: a prespecified analysis of heart rate and heart rhythm in the FINEARTS-HF trialMisato Chimura, Pardeep S Jhund, Alasdair D Henderson, et al.
JACC. Heart Failure|March 26, 2026
Effects of Finerenone on Heart Failure Outcomes According to Baseline Heart Failure Risk in Chronic Kidney Disease and Type 2 DiabetesJohn W Ostrominski, Brendon L Neuen, Brian L Claggett, et al.
Biorxiv : the Preprint Server for Biology|March 10, 2025
Mineralocorticoid Receptor Antagonism Reduces Atrial Arrhythmias Post-Cardiac Surgery and Attenuates Atrial Stress Responses to Cardioplegic ArrestSina Danesh, Fazal Khan, Trevor Chopko, et al.
European Journal of Heart Failure|April 1, 2024
Impact of baseline kidney dysfunction on oral diuretic efficacy following hospitalization for heart failure - insights from TRANSFORM-HFPieter Martens, Stephen J Greene, Robert J Mentz, et al.
Circulation|April 13, 2026
Dysregulated Aldosterone Production in Obesity Is Associated With Adverse Cardiac Structure, Function, and AdiposityCheng-Hsuan Tsai, Justin M Chan, Julia Milks, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|January 13, 2023
Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysisGerasimos Filippatos, Stefan D Anker, Phyllis August, et al.
JACC. Heart Failure|June 4, 2016
Heart Failure Clinical Trials in East and Southeast Asia: Understanding the Importance and Defining the Next StepsRobert J Mentz, Lothar Roessig, Barry H Greenberg, et al.
European Journal of Heart Failure|September 8, 2025
Finerenone according to insulin resistance in heart failure: Insights from the FINEARTS-HF trialJohn W Ostrominski, Brian L Claggett, Akshay S Desai, et al.
Kidney Medicine|September 25, 2023
Finerenone in Hispanic Patients With CKD and Type 2 Diabetes: A Post Hoc FIDELITY AnalysisSylvia E Rosas, Luis M Ruilope, Stefan D Anker, et al.
European Journal of Heart Failure|July 24, 2019
Application of the H<sub>2</sub> FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trialPeder L Myhre, Muthiah Vaduganathan, Brian L Claggett, et al.
Pageof 69

Showing results (551-560 of 688) with videos related to

Sort By:
Pageof 69
European Journal of Heart Failure|March 2, 2026
Efficacy of finerenone in patients with heart failure and mildly reduced or preserved ejection fraction: a prespecified analysis of heart rate and heart rhythm in the FINEARTS-HF trialMisato Chimura, Pardeep S Jhund, Alasdair D Henderson, et al.
JACC. Heart Failure|March 26, 2026
Effects of Finerenone on Heart Failure Outcomes According to Baseline Heart Failure Risk in Chronic Kidney Disease and Type 2 DiabetesJohn W Ostrominski, Brendon L Neuen, Brian L Claggett, et al.
Biorxiv : the Preprint Server for Biology|March 10, 2025
Mineralocorticoid Receptor Antagonism Reduces Atrial Arrhythmias Post-Cardiac Surgery and Attenuates Atrial Stress Responses to Cardioplegic ArrestSina Danesh, Fazal Khan, Trevor Chopko, et al.
European Journal of Heart Failure|April 1, 2024
Impact of baseline kidney dysfunction on oral diuretic efficacy following hospitalization for heart failure - insights from TRANSFORM-HFPieter Martens, Stephen J Greene, Robert J Mentz, et al.
Circulation|April 13, 2026
Dysregulated Aldosterone Production in Obesity Is Associated With Adverse Cardiac Structure, Function, and AdiposityCheng-Hsuan Tsai, Justin M Chan, Julia Milks, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|January 13, 2023
Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysisGerasimos Filippatos, Stefan D Anker, Phyllis August, et al.
JACC. Heart Failure|June 4, 2016
Heart Failure Clinical Trials in East and Southeast Asia: Understanding the Importance and Defining the Next StepsRobert J Mentz, Lothar Roessig, Barry H Greenberg, et al.
European Journal of Heart Failure|September 8, 2025
Finerenone according to insulin resistance in heart failure: Insights from the FINEARTS-HF trialJohn W Ostrominski, Brian L Claggett, Akshay S Desai, et al.
Kidney Medicine|September 25, 2023
Finerenone in Hispanic Patients With CKD and Type 2 Diabetes: A Post Hoc FIDELITY AnalysisSylvia E Rosas, Luis M Ruilope, Stefan D Anker, et al.
European Journal of Heart Failure|July 24, 2019
Application of the H<sub>2</sub> FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trialPeder L Myhre, Muthiah Vaduganathan, Brian L Claggett, et al.
Pageof 69